Sana Biotechnology logo

Sana Biotechnology

sana.com

Sana Biotechnology develops engineered cell and gene therapies to repair, control, or replace cells in order to address the underlying causes of diseases such as diabetes, B-cell cancers, and B-cell related autoimmune disorders. Its mission is to create novel medicines that meaningfully improve patient outcomes and broaden access to transformative treatments.

Facts

Sectors
Biotechnology, Gene editing, Cell therapy, Biopharmaceuticals
Type
Corporation Seattle business license
Registered name
Sana Biotechnology Inc Seattle business license
Stage
Public
Members see funding amounts.
.

Is this your organization? Claim it

Recent coverage

Front-page news, podcasts and videos about Sana Biotechnology

See all 62

Yoodli launches AI platform to build courses, coach employees and track workplace skill gains after $300M+ valuation

Yoodli is expanding from AI practice sessions for public speaking into an “AI platform for human skills” that builds training courses, coaches employees during meetings, answers workplace questions, and tracks skill improvement. The startup—valued at over $300 million in December and backed with nearly $60 million from investors—aims to move into corporate training alongside firms like Workday and LinkedIn.

Nobel Laureate David Baker Drives Protein Design Innovation and Startup Growth at University of Washington

David Baker, Nobel Prize winner and head of the Institute for Protein Design at the University of Washington, is focused on advancing protein design research and entrepreneurship, having helped spawn over 20 startups in Seattle's biotech hub. He plans to continue accelerating scientific innovation in the field, which develops new proteins for therapeutics, vaccines, and materials.

By Sana Biotechnology

See all 9

Sana Biotechnology says SC451 Phase 1/2 and SG293 clinical studies nearing start; Q2 cash $160.5M, runway into mid-2027

Sana Biotechnology reported Q2 2026 progress toward initiating Phase 1/2 trial for SC451 in type 1 diabetes and a clinical study for SG293 in non-Hodgkin lymphoma, highlighted by NEJM publication and upcoming EASD presentation for UP421 clinical data. The company presented SG293 and SG227 preclinical data, advanced a Mayo Clinic collaboration, and reported $160.5M cash with runway into mid-2027.

People

  • Steve Harr Co-founder and President and Chief Executive Officer
  • Snehal Patel Executive, Executive Vice President and Chief Technical Officer

Online

Questions about Sana Biotechnology

What is Sana Biotechnology?

Sana Biotechnology is a public company developing engineered cell and gene therapies to repair, control, or replace cells and address the underlying causes of diseases such as diabetes, B-cell cancers, and B-cell related autoimmune disorders.

What has Sana Biotechnology been in the news for?

GeekWire reported in February 2026 that Sana Biotechnology appointed Brian Piper as CFO.

Who are the people behind Sana Biotechnology?

Steve Harr is co-founder, president and chief executive officer of Sana Biotechnology. Snehal Patel is executive vice president and chief technical officer.

Who invested in Sana Biotechnology, and how much has it raised?

Members of Seattle Flow see Sana Biotechnology's funding rounds, amounts and investors on its Funding tab. Joining is free.

When was Sana Biotechnology founded?

Sana Biotechnology was founded in 2018.